Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study

Not yet recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Coronary Artery DiseaseCoronary Artery Disease ProgressionCoronary Artery StenosisCoronary Artery RestenosisInflammationInflammatory DiseaseInflammation Vascular
Interventions
BEHAVIORAL

Healthy life style

Healthy diet, regular exercise, and quitting smoking

DRUG

Secondary prevention for atherosclerotic coronary artery disease

Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

DRUG

Immunosuppressive Therapy

Glucocorticoids and/or immunosuppressive agents

PROCEDURE

Coronary revascularization

Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

DRUG

Supportive therapies

Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER